Hey, wait a sec­ond. What about Roche’s PhI­II he­mo­phil­ia A drug?

Large­ly over­shad­owed by Bio­Marin’s po­ten­tial­ly land­mark gene ther­a­py re­sults for he­mo­phil­ia A, a group from Roche’s Chugai sub­sidiary turned up at the same sci­en­tif­ic con­fer­ence …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA